Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/21/2025

Hepatorenal Syndrome Treatment

Introduction to Treatment

  • The initial dose of terlipressin is 1 mg IV every 4-6 hours, which can be increased to 2 mg every 4-6 hours if serum creatinine does not decrease by at least 25% by day 3 of treatment, as recommended by the Journal of Hepatology and American Association for the Study of Liver Diseases guidelines 1, 2, 3

Dosing and Administration

  • Continuous infusion of terlipressin at the same daily doses (2-12 mg/24h) is an effective alternative to bolus dosing, according to the Anaesthesia guidelines 4
  • Albumin should be administered concurrently with terlipressin, with an initial dose of 1 g/kg on day 1 (maximum 100 g) and a maintenance dose of 20-40 g/day thereafter, as recommended by the Journal of Hepatology guidelines 2, 3, 5, 6, 7

Treatment Duration and Efficacy

  • The maximum treatment duration is 14 days, and the median time to response is approximately 14 days, usually shorter in patients with lower baseline serum creatinine, as reported by the Journal of Hepatology guidelines 2
  • Treatment is effective in 40-50% of patients with hepatorenal syndrome (HRS), characterized by a progressive reduction in serum creatinine, increase in arterial pressure, urine volume, and serum sodium concentration, according to the Journal of Hepatology and American Association for the Study of Liver Diseases guidelines 1, 2
  • The reversal rate of Hepatorenal Syndrome Type 1 is 36-44% with terlipressin versus 13-15% with placebo, and approximately 40-50% of patients show improvement in renal function, with a median response time of 14 days 1, 2

Predictors of Response and Alternative Treatments

  • Predictors of positive response to terlipressin treatment include serum bilirubin <10 mg/dl before treatment, increase in mean arterial pressure >5 mmHg at day 3 of treatment, and lower baseline serum creatinine, as identified by the Journal of Hepatology guidelines 2
  • Norepinephrine (0.5-3 mg/h as continuous infusion) is a viable alternative to terlipressin if central venous access is available, as suggested by the Anaesthesia and Journal of Hepatology guidelines 2, 4
  • Midodrine plus octreotide is less effective but can be used when terlipressin is unavailable, according to the Anaesthesia guidelines 4
  • Midodrine has similar efficacy to terlipressin, with a dosing range of 0.5-3.0 mg/h in continuous infusion, but requires monitoring in an intensive care unit, and is less effective than terlipressin when used in non-monitored settings (28.6% vs 70.4% reversal of Hepatorenal Syndrome) 1, 7, 3, 5, 6

Contraindications and Side Effects

  • Contraindications include hypoxemia (oxygen saturation <90%), ischemic heart disease, acute-on-chronic liver failure grade 3, and high MELD scores (≥35) 1, 3, 5
  • Cardiovascular or ischemic complications are reported in approximately 12% of patients, and common side effects of terlipressin include respiratory complications (8-30% of patients), hyponatremia, abdominal pain, and diarrhea 2, 3, 1, 5
  • The following table summarizes the incidence of respiratory failure in patients treated with terlipressin compared to placebo:
Incidence Terlipressin Placebo
Respiratory Failure 14-30% 5%

5

Monitoring and Treatment Discontinuation

  • Regular monitoring of vital signs, especially blood pressure and heart rate, continuous pulse oximetry for respiratory status, renal function tests, and careful clinical screening including ECG before starting treatment are recommended 8, 1, 5
  • Treatment should be continued until serum creatinine returns to ≤0.3 mg/dL of the baseline value for 2 consecutive days, with a maximum treatment duration of 14 days, and should be discontinued if SpO₂ <90%, cardiac or ischemic symptoms occur, or if there is no response after 3-4 days with maximum tolerated doses 5, 6, 1